
Supporting Information

Identification of HSP90 as a direct target of artemisinin for its anti-inflammatory activity via quantitative chemical proteomics

Guolin Wu,^a Bao Cheng,^a Hui Qian,^a Shengming Ma^{a,b} and Qin Chen,^{*,a}

^a Research Center for Molecular Recognition and Synthesis, Department of Chemistry, Fudan University, 220 Handan Lu, Shanghai 200433, P. R. China

^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Lu, Shanghai 200032, P. R. China

*
E-mail: chenq@fudan.edu.cn


Table of Contents

1. Synthesis of the ART probe (2)	page S1-S7
2. Supplementary Figure S1, S2, S3	page S8
3. Supporting Table: full list of protein targets of ART	page S9
4. References	page S9
5. ¹ H NMR spectra for 2-7 and ¹³ C NMR spectrum for 2	page S9-S16

1. Synthesis of the ART probe (2)

1.1 General Information. NMR spectra were taken with an Agilent-400 spectrometer (400 MHz for ^1H NMR, 100 MHz for ^{13}C NMR) in CDCl_3 . All ^1H NMR experiments were measured with tetramethylsilane (δ 0 ppm) in CDCl_3 as the internal reference and coupling constants were reported in Hz; ^{13}C NMR experiments were measured in relative to the signal of CDCl_3 (δ 77.0 ppm). Column chromatography was performed on silicagel H (300-400 mesh). Petroleum ether (b.p. 60-90 $^\circ\text{C}$), ethyl acetate and dichloromethane were purchased from Shanghai Titan Scientific Co., Ltd.; Artemisinin and 2-propynamine (98%) were purchased from Shanghai D&B Biological Science and Technology Co., Ltd.; NaBH_4 , BzCl , pyridine, and DMAP were purchased from Sinopharm Chemical Reagent Co., Ltd.; Allyltrimethylsilane (97%) was purchased from Shanghai Shaoyuan Co., Ltd.; Oxone (95%) and EDCI (97%) were purchased from Shanghai Bide Pharmatech Co., Ltd.; Other reagents were purchased from commercial sources and used without further purification.

1.2 Synthesis of 2




Compound **2** was prepared according to the literature method with slight

modification.¹⁻⁶


1.3 Experimental details and analytical data

1.3.1 Synthesis of **3** (dihydroartemisinin, wgl-1-023)



The dihydroartemisinin **2** was synthesized according to the reported procedures with slight modifications.¹ To a flask was added artemisinin (2.2587 g, 98%, 8.0 mmol) and MeOH (20 mL) under argon atmosphere. Then a solution of NaBH₄ (907.4 mg, 98%, 24.0 mmol) in MeOH (10 mL) was added dropwise over 10 min at 0 °C via ice-water bath. After stirred at this temperature for 3 h, the solution was slowly poured into a mixture of AcOH/H₂O (5 mL/100 mL). The resulting mixture was stirred under the ice/water bath for 0.5 h and then left standing for another 0.5 h. A white solid was isolated by filtration, washed with water and dried in vacuum to give **3** (1.9073 g, 86%). ¹H NMR (400 MHz, CDCl₃) δ 5.62 (s, 1 H), 5.35-5.25 (m, 1 H), 3.17 (s, 1 H), 2.60 (s, 1 H), 2.38 (td, *J*₁ = 14.0, *J*₂ = 3.7 Hz, 1 H), 2.11–1.97 (m, 1 H), 1.96–1.74 (m, 3 H), 1.71–1.60 (m, 1 H), 1.59–1.18 (m, 7 H), 1.05–0.82 (m, 7 H). The characterization data matches the previous reported in literature.²


1.3.2 Synthesis of **4** (dihydroartemisinin 10 α -benzoate, wgl-1-024)



The dihydroartemisinin 10 α -benzoate **4** was synthesized according to the reported procedures with slight modifications.² To a flask was added dihydroartemisinin **3**

(1.7656 g, 6.2 mmol) and CH_2Cl_2 (25 mL) under argon atmosphere. After cooling to 0°C via ice-water bath, pyridine (2.5 mL, $d = 0.983\text{ g}\cdot\text{cm}^{-3}$, 2.4575 g, 31.0 mmol) and benzoyl chloride (1.1365 g, 98%, 8.1 mmol) in CH_2Cl_2 (5 mL) were added to the stirred solution over 5 min. The resulting mixture was naturally warmed up to room temperature, stirred for 11.5 h, and quenched with a saturated aqueous ammonium chloride solution (10 mL). The organic layer was separated, and washed with H_2O (10 mL), brine (10 mL). The organic layer was then dried over anhydrous Na_2SO_4 and concentrated, and the residue was purified by column chromatography [eluent: petroleum ether/ethyl acetate = 10:1 (550 mL) to 5:1 (180 mL)] to yield **4** as a white solid (2.1826 g, 91%). ^1H NMR (400 MHz, CDCl_3) δ 8.17–8.07 (m, 2 H), 7.57 (t, $J = 7.6$ Hz, 1 H), 7.44 (t, $J = 7.6$ Hz, 2 H), 6.01 (d, $J = 10.0$ Hz, 1 H), 5.53 (s, 1 H), 2.83–2.68 (m, 1 H), 2.39 (td, $J_1 = 13.9$ Hz, $J_2 = 3.9$ Hz, 1 H), 2.11–1.98 (m, 1 H), 1.97–1.87 (m, 1 H), 1.86–1.64 (m, 3 H), 1.58–1.21 (m, 7 H), 1.12–0.86 (m, 7 H). The characterization data matches the previous reported in literature.²


1.3.3 Synthesis of **5** (10 β -Allyldeoxoartemisinin, wgl-1-029)



The 10 β -Allyldeoxoartemisinin **5** was synthesized according to the reported procedures with slight modifications.³ To an oven-dried flask was added ZnCl_2 (852.3 mg, 6.2 mmol), 4 Å molecular sieves (200 mg) in the glovebox. After cooling to 0°C via ice-water bath, 1,2-dichloroethane (15 mL), allyltrimethylsilane (4.1 mL, 97%, $d = 0.719\text{ g}\cdot\text{cm}^{-3}$, 2.9479 g, 25.8 mmol) and **4** (2.0013 g, 5.2 mmol, in 15 mL 1,2-dichloroethane) were added to the mixture under argon atmosphere. The mixture was naturally warmed up to room temperature and stirred for 5 h. The mixture was quenched with a saturated aqueous NaHCO_3 solution (2 mL), and diluted with ethyl

acetate (80 mL). Then the mixture was washed with H₂O (20 mL x 2), followed by brine (20 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography [eluent: petroleum ether/ethyl acetate = 30:1 (310 mL) to 20:1 (630 mL)] to give **5** as a white solid (1.3504 g, 85%). ¹H NMR (400 MHz, CDCl₃) δ 6.00–5.83 (m, 1 H), 5.33 (s, 1 H), 5.18–4.99 (m, 2 H), 4.37–4.24 (m, 1 H), 2.68 (sextet, *J* = 7.0 Hz, 1 H), 2.48–2.24 (m, 2 H), 2.24–2.14 (m, 1 H), 2.11–1.97 (m, 1 H), 1.96–1.87 (m, 1 H), 1.86–1.75 (m, 1 H), 1.74–1.57 (m, 2 H), 1.51–1.17 (m, 7 H), 1.03–0.92 (m, 4 H), 0.88 (d, *J* = 8.0 Hz, 3 H). The characterization data matches the previous reported in literature.³


1.3.4 Synthesis of 10-(2-Oxoethyl)deoxoartemisinin (**6**, wgl-1-033)



The 10-(2-Oxoethyl)deoxoartemisinin **6** was synthesized according to the reported procedures with slight modifications.⁴ To a flask was added **5** (616.5 mg, 2.0 mmol) and acetonitrile (30 mL). Then NaIO₄ (856.2 mg, 4.0 mmol, dissolved in 5 mL of water) and RuCl₃ (14.7 mg, 97%, 0.07 mmol, dissolved in 100 μL of H₂O) was added to the mixture at room temperature. After the disappearance of **5** in 5.5 h as indicated by TLC, ethyl acetate (40 mL) was added to the reaction mixture. The organic layer was washed with water (20 mL x 2) and brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography [eluent: petroleum ether/ethyl acetate = 4:1 (100 mL) to 2:1 (150 mL)] to give **6** (413.3 mg, 67% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 9.80 (t, *J* = 1.6 Hz, 1 H, CHO), 5.32 (s, 1 H), 5.01–4.89 (m, 1 H), 2.81–2.63 (m, 2 H), 2.50–2.40 (m, 1 H), 2.39–2.27 (m, 1 H), 2.09–1.99 (m,


1 H), 1.98–1.87 (m, 1 H), 1.84–1.75 (m, 1 H), 1.74–1.62 (m, 2 H), 1.50–1.36 (m, 4 H), 1.35–1.20 (m, 3 H), 1.04–0.93 (m, 4 H), 0.87 (d, $J = 7.6$ Hz, 3 H). The characterization data matches the previous reported in literature.⁵

1.3.5 Synthesis of **7** (wgl-1-040)



The intermediate **7** was synthesized according to the reported procedures with slight modifications.⁴ To a flask was added **6** (310.5 mg, 1.0 mmol) and acetonitrile (30 mL). Then NaHCO₃ (421.7 mg, 5.0 mmol, dissolved in 5 mL of H₂O) and oxone (1.2302 g, 2.0 mmol, 95%, dissolved in 2 mL of H₂O) were added dropwise over 20 min at room temperature. After stirring for an additional 2 h, the reaction mixture was quenched with hydrochloride acid (5 mL, 2 M) and diluted with ethyl acetate (40 mL). The mixture was washed with water (20 mL x 2) and brine (10 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue **7** (360.3 mg) as a white solid was pure enough (which contains some EtOAc residue) for the following steps. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (brs, 1 H, COOH), 5.29 (s, 1 H), 4.80–4.67 (m, 1 H), 2.74–2.52 (m, 2 H), 2.49–2.36 (m, 1 H), 2.33–2.16 (m, 1 H), 1.97–1.90 (m, 1 H), 1.89–1.79 (m, 1 H), 1.78–1.67 (m, 1 H), 1.66–1.51 (m, 2 H), 1.44–1.11 (m, 7 H), 0.99–0.71 (m, 7 H). The characterization data matches the previous reported in literature.⁴

1.3.6 Synthesis of **10 β** -(Acetamidomethylalkyne)deoxoartemisinin (**2**, wgl-1-043)



The compound **2** was synthesized according to the reported procedures with slight modifications.⁶ To a flask was added **7** (360.3 mg, 1.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 480.1 mg, 97%, 2.5 mmol), 4-dimethylaminopyridine (DMAP, 244.1 mg, 2.0 mmol), and CH_2Cl_2 (20 mL) at room temperature. Then 2-propynamine (0.3 mL, 98%, $d = 0.86 \text{ g}\cdot\text{cm}^{-3}$, 252.8 mg, 4.6 mmol) was added to the stirred mixture. The resulting mixture was stirred for 18 h at room temperature. Then the solvent was removed under reduced pressure. The residue was extracted with ethyl acetate (20 mL). The resulting mixture was washed with saturated NaHCO_3 solution (5 mL), water (10 mL x 2), and brine (10 mL), then dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography [eluent: petroleum ether/ethyl acetate/ethyl ether = 10:5:1 (160 mL)] and then recrystallized from CH_2Cl_2 /petroleum ether to afford **2** (385.5 mg, 96%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 5.40 (s, 1 H), 4.82 (s, 1 H), 4.05 (s, 2 H), 2.85–0.45 (m, 26 H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 102.8, 90.2, 80.7, 79.7, 71.2, 69.1, 51.6, 43.2, 37.5, 37.3, 36.4, 34.1, 30.3, 28.9, 25.8, 24.73, 24.69, 19.9, 11.8. The purity of this compound was proven by ^1H and ^{13}C NMR spectra.

2 Supplementary Figures




Fig S1. GO analysis of biological pathways that are potentially associated with ART target proteins.




Fig S2. Target profiles of ART are shown by a scattered plot. The dots represent proteins with competitive ratios and p -values above 1.3 and 0.05 ($-\log_{10}$ corresponds to 1.3) respectively. The proteins colored in yellow are the proteins which have been identified in malaria parasites and cancer cells.




Fig S3. Lipopolysaccharide (LPS) time-dependently induced the expression of iNOS. A representative blot of three experiments is shown.


3 Supporting Table: full list of protein targets of ART

(Please see the attached EXCEL file)

4 References

1. Y. Liu, K. Cui, W. Lu, W. Luo, J. Wang, J. Huang and C. Guo, *Molecules*, 2011, **16**, 4527-4538.
2. J. Wang, C. J. Zhang, W. N. Chia, C. C. Loh, Z. Li, Y. M. Lee, Y. He, L. X. Yuan, T. K. Lim, M. Liu, C. X. Liew, Y. Q. Lee, J. Zhang, N. Lu, C. T. Lim, Z. C. Hua, B. Liu, H. M. Shen, K. S. Tan and Q. Lin, *Nat Commun*, 2015, **6**, 10111.
3. S. Hindley, S. A. Ward, R. C. Storr, N. L. Searle, P. G. Bray, B. K. Park, J. Davies and P. M. O'Neill, *J Med Chem*, 2002, **45**, 1052-1063.
4. Y. Liu, V. K. Wong, B. C. Ko, M. K. Wong and C. M. Che, *Org Lett*, 2005, **7**, 1561-1564.
5. J. Ma, E. Katz, D. E. Kyle and H. Ziffer, *J Med Chem*, 2000, **43**, 4228-4232.
6. H. M. Ismail, V. Barton, M. Phanchana, S. Charoensutthivarakul, M. H. Wong, J. Hemingway, G. A. Biagini, P. M. O'Neill and S. A. Ward, *Proc Natl Acad Sci U S A*, 2016, **113**, 2080-2085.

5. ¹H NMR spectra for 2-7 and ¹³C NMR spectrum for 2



wjrl-1-023_20180419_01.fid
 Apr 19 2018
 Recycle delay = 5.000 sec
 NA = 8
 Solvent = cdcl3
 F1 = 399.749542 MHz
 F2 = 100.526031 MHz




Fig S4. ¹H NMR (400 MHz, CDCl₃) spectrum for **3**.




Fig S5. ¹H NMR (400 MHz, CDCl₃) spectrum for **4**




Fig S6. ¹H NMR (400 MHz, CDCl₃) spectrum for **5**




Fig S7. ¹H NMR (400 MHz, CDCl₃) spectrum for **6**




Fig S8. ^1H NMR (400 MHz, CDCl_3) spectrum for 7

